Mike Murtagh

Michael Murtagh is the Senior Vice President, Regulatory Affairs at Vedere Bio II. Prior to Vedere, he served as Vice President, Regulatory Affairs, at Astellas Gene Therapies (formerly known as Audentes Therapeutics) where he led the regulatory strategy of multiple gene therapy programs from research through clinical development. Before Astellas, Michael served as Director, Regulatory Affairs at BioMarin Pharmaceutical Inc. where he was the regulatory lead on the Brineura (cerliponase alfa) and Talzenna (talozaprib) programs from research through clinical development. He received a B.S. in biology from the University of San Francisco.